Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin/Bicillin Syphilis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is 18 to 55 years of age.~* The subject has signed written informed consent.~* The subject has untreated primary \[darkfield or Treponema (T.) pallidum by a rapid, direct, fluorescent antibody darkfield (DFA-TP)\] positive genital ulcers, secondary (based on classical palmar/plantar rash, condylomata lata, mucous patches, etc. or darkfield or DFA-TP positive lesions), or early latent syphilis (e.g., current reactive serologic tests for syphilis (STS), and a documented non-reactive STS or documented sexual exposure to a known early latent, primary or secondary syphilis patient in last 12 months; identification of this sexual contact must occur within 60 days of admission into the study).~* The subject has laboratory evidence of syphilis, i.e., reactive serologic test for syphilis (RPR).~* The subject is not pregnant, as documented by a negative urine or serum pregnancy test, or lactating.~* The subject is willing to have an HIV test, and, participate in HIV counseling and return to the clinic for follow-up treatment.~Exclusion Criteria:~* The subject does not have reactive serologic tests for syphilis.~* The subject has latent syphilis of unknown duration, late latent syphilis or evidence of neurosyphilis.~* The subject has a known or suspected allergy to macrolide or azalide antibiotics.~* The subject has a known or suspected sexually transmitted disease (STD), other than syphilis requiring treatment with a drug, other than azithromycin, active against T. pallidum.~* The subject has used antibiotics active against T. pallidum in the preceding 30 days. (Note: the use of antimicrobials known to NOT be effective against T. pallidum such as quinolones, sulfonamides, trimethoprim, metronidazole and spectinomycin will be allowed).~* The subject is known to be HIV positive prior to enrollment.~* The subject has suspected or known ongoing drug use that might interfere with study participation and follow-up treatment.~* The subject has a history of cardiovascular disease, known immunosuppression, or known AIDS, which might compromise response to therapy.~* The subject is judged by the investigators to be unlikely to reliably participate in the study follow-up.~* The subject has used any investigational drugs in the past 30 days.~* The subject has any other condition that may impair drug absorption (malabsorption syndrome or active peptic ulcer disease).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Azithromycin 2.0 gram single oral dose.
- Benzathine Penicillin (Type: ACTIVE_COMPARATOR): Benzathine penicillin 2.4 million units administered intramuscularly. Doxycycline will be administered if the patient is allergic to Benzathine Penicillin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete